These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 6432393)

  • 1. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract]   [Full Text] [Related]  

  • 2. L-threo-3, 4-dihydroxyphenylserine treatment of Parkinson's disease.
    Ogawa N; Yamamoto M; Takayama H
    J Med; 1985; 16(5-6):525-34. PubMed ID: 3938472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].
    Narabayashi H; Yokochi F; Ogawa T; Igakura T
    No To Shinkei; 1991 Mar; 43(3):263-8. PubMed ID: 1907469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pure akinesia presenting with antecollis].
    Ota S; Tsuchiya K
    No To Shinkei; 2005 Oct; 57(10):893-8. PubMed ID: 16277235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
    Narabayashi H; Kondo T; Yokochi F; Nagatsu T
    Adv Neurol; 1987; 45():593-602. PubMed ID: 3103397
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease.
    Yamamoto M; Ogawa N; Ujike H
    J Neurol Sci; 1986 Mar; 73(1):39-44. PubMed ID: 3084714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of pure akinesia with L-threo-3,4-dihydroxyphenylserine (DOPS): report of a case, with pharmacological considerations.
    Yamamoto M; Ujike H; Ogawa N
    Clin Neuropharmacol; 1985; 8(4):334-42. PubMed ID: 2416437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients.
    Yoshida M; Noguchi S; Kuramoto S
    Kurume Med J; 1989; 36(2):67-74. PubMed ID: 2511378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3, 4-dihydroxyphenylserine.
    Ogawa N; Kuroda H; Yamamoto M; Nukina I; Ota Z
    Acta Med Okayama; 1984 Jun; 38(3):301-4. PubMed ID: 6431755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of L-threo-DOPS on P-300 in parkinsonism].
    Yokota J; Itoh T; Imai H; Narabayashi H
    Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DL-threo-3,4-dihydroxyphenylserine for freezing symptom in parkinsonism.
    Narabayashi H; Kondo T; Nagatsu T; Hayashi A; Suzuki T
    Adv Neurol; 1984; 40():497-502. PubMed ID: 6421112
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
    Narabayashi H
    No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.
    Suzuki T; Sakoda S; Ueji M; Kishimoto S; Hayashi A; Kondo T; Narabayashi H
    Neurology; 1984 Nov; 34(11):1446-50. PubMed ID: 6436731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effective of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in hypersomnia and subcortical dementia caused by bilateral medial thalamic and midbrain infarcts].
    Komiya T; Narabayashi H; Kondo T
    Rinsho Shinkeigaku; 1988 Mar; 28(3):268-71. PubMed ID: 3135970
    [No Abstract]   [Full Text] [Related]  

  • 15. Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease.
    Teelken AW; van den Berg GA; Muskiet FA; Staal-Schreinemachers AL; Wolthers BG; Lakke JP
    J Neural Transm Park Dis Dement Sect; 1989; 1(3):177-88. PubMed ID: 2476157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of L-threo-3,4-dihydroxyphenylserine on regional cerebral blood flow in patients with Parkinson's disease.
    Ujike H; Yamamoto M
    J Neurol Sci; 1988 Jan; 83(1):75-80. PubMed ID: 3126272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease.
    Fukada K; Endo T; Yokoe M; Hamasaki T; Hazama T; Sakoda S
    Med Hypotheses; 2013 Feb; 80(2):209-12. PubMed ID: 23265352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W; Birkmayer G; Lechner H; Riederer P
    J Neural Transm; 1983; 58(3-4):305-13. PubMed ID: 6420517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.